key: cord-0932211-bw4ovaq3
authors: Sen, Mrittika; Honavar, Santosh G
title: After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines
date: 2021-11-26
journal: Indian J Ophthalmol
DOI: 10.4103/ijo.ijo_2824_21
sha: e89d9d0a523532558ae9e8abc234b435afba30e0
doc_id: 932211
cord_uid: bw4ovaq3

Several COVID-19 vaccines have been developed and approved for use around the world from December 2020, to combat the pandemic caused by the novel SARS-CoV-2 virus. Several ophthalmic manifestations of the COVID-19 vaccines have been reported by ophthalmologists. This review was undertaken to recognize, encourage active reporting and determine the pathogenesis and time of appearance for better awareness and understanding of the ophthalmic manifestations of COVID-19 vaccines. A literature search was performed for publications on the ophthalmic manifestations of COVID-19 vaccines between January 1, 2021 and November 7, 2021. 23 case reports, 17 letters to editors, 3 ophthalmic images, 4 brief communications, 4 retrospective cohort studies and 2 case control studies were included. Posterior segment, including the uvea, choroid and retinal vasculature, was most commonly affected and the reported clinical features developed at a median of four days from the time of vaccination. The possible mechanisms include molecular mimicry of the vaccine components with host ocular tissues, antigen-specific cell and antibody-mediated hypersensitivity reactions to viral antigens and adjuvants present in the vaccines. The causal relationship of the ocular signs and symptoms and COVID-19 vaccines has not been established and requires long-term and large multicentre data. Most of the reported manifestations are mild, transient and adequately treated when diagnosed and managed early. The benefits of COVID-19 vaccination outweighs the reported rare adverse events and should not be a deterrent to vaccination.

Sen and Honavar: After the storm 

The eyelid involvement was transient in all cases limited to unilateral erythematous edema and bilateral purpuric rash. All cases were after the Pfizer-BioNTech mRNA vaccine. The three cases of acute onset eyelid edema reported by Austria et al. [7] resolved with observation, antihistamine, and oral corticosteroids, respectively, within 1-2 days. The purpuric rash observed in three patients developed at a median of 18 days and resolved spontaneously within 10-15 days. The coagulation profile was normal in all three. [8] [ Fig. 1 ] Eyelid edema can be a part of an anaphylactic reaction, but none of the patients reported any systemic adverse effects. Periorbital swelling is seen in ocular vaccinia after the smallpox vaccine, and ocular respiratory syndrome is reported with the influenza vaccine. [8] The mechanisms proposed after COVID-19 vaccination include complement-induced reaction and molecular mimicry with an autoimmune response.

Corneal graft rejection was the most common anterior segment manifestation of the COVID-19 vaccine. Seven of the nine cases were following the Pfizer-BioNTech mRNA vaccine at a median duration of 7 (mean 10.3 ± 7.2) days. The remaining two received the viral vector-based Covishield vaccine. Four patients had undergone penetrating keratoplasty, whereas the rest had undergone lamellar keratoplasty. Five of eight patients were on topical corticosteroids at the time of vaccination. In the case reported by Phylactou et al., the patient also had a retroviral infection and was on treatment for the same. [11] Three patients had bilateral corneal transplants and of these, one patient developed rejection in only one eye. Five eyes had undergone repeat transplants following prior failures. Only one patient developed systemic symptoms, moderate chills, and myalgia following the vaccination. [9] The symptoms and signs were typical of endothelial graft rejection with acute onset of diminution of vision, redness, photophobia with or without pain, graft edema, Descemet's folds, and anterior chamber (AC) reaction. [Figs. 2 and 3] Treatment was with frequent (1-2 hourly) administration of topical corticosteroids with or without oral steroids. Acyclovir/Valacyclovir was started in two patients to counter a possible viral infection. [9, 14] All the patients recovered within 1-4 weeks. 

Austria et al. [7] Letter to editor Mazzatenta et al. [8] Letter to editor Rallis et al. [9] Brief communication UK Phylactou et al. [11] OD Acute onset blurred vision, redness, photophobia, OD 6/36, diffuse corneal edema, KPs, AC 1+cells

Acute corneal endothelial graft rejection The cornea is an immunoprivileged organ, and corneal transplantation has the highest rate of success. Lamellar keratoplasty has ensured further protection of the graft. Graft rejection can follow the breakdown of the blood-ocular barrier following intraocular inflammation or recurrent viral infection. [11] Corneal graft rejection after immunization has been reported with influenza, hepatitis B, tetanus, and yellow fever vaccines. [10, 11] Bilateral graft failure in two of three patients with transplants in both eyes, and the temporal sequence of events points towards the role of the COVID-19 vaccine. The suggested mechanisms of graft failure are the vaccine-induced immune enhancement and cross-reactivity of virus antigen-specific T-cells with HLA antigen-disparate corneal allograft endothelial cells, increased vascular permeability after the vaccination, and presence of mRNA in the aqueous following a prior COVID-19 infection. [14] The COVID-19 vaccine induces a strong antibody response with CD4 + Th1 cells, which are also mediators of corneal graft rejection. [10] Systemic reactogenicity would be more likely after the second dose of vaccination than the first one, but seven of the nine patients developed rejection after the first dose itself. Also, none of the patients were reported to have had prior COVID-19 infection, but one cannot rule out mild, asymptomatic infection. Nevertheless, the possibility of graft rejection following immunization necessitates considering deferral of elective corneal transplants by 3-6 months after the final dose of COVID-19 vaccine and initiating corneal transplant patients on topical corticosteroids before the first dose of vaccine and continuing for a month after the second dose. [10] Patients with repeat grafts and immunocompromised state are at a higher risk of rejection and should be forewarned. While all patients recovered, it must be borne in mind that endothelial cell loss following graft rejection is irreplaceable.

Pichi et al. reported a case series of seven patients with a mean age of 41.4 years who developed ocular complaints following the first dose of the inactivated Sinopharm vaccine. [16] Four eyes of three patients developed episcleritis and scleritis at a mean of 5.2 days. One patient had a history of rheumatoid arthritis, was on sulfasalazine and presented with scleritis. Tapering doses of topical corticosteroid were prescribed, and the inflammation resolved in all the cases. Scleritis and episcleritis have been reported after the administration of live attenuated vaccines as well as post-COVID-19 infection. [6, 17] 

The retina and the uvea are the most commonly involved ocular structures following COVID-19 vaccination with 50 cases reported in the literature, 21 being contributed by a retrospective study from Israel [ Table 3 ]. [16, The mean age was 43.6 ± 17.2 (median 40) years with 23 males and 23 females (unspecified in 4). The symptoms developed at a median interval of 4 (mean 7.4 ± 8.5 ) days from the time of vaccination. None of the patients had a prior history of COVID-19 although one patient with panuveitis tested positive for COVID-19 post-vaccination. [27] Thirty patients had received the Pfizer-BNT mRNA vaccine, the adenoviral vector-based vaccines by AstraZeneca and Serum Institute of India were given to 11 patients, whereas the vector-based vaccine by Johnson and Johnson had been used in one patient. One patient had received the Sputnik V vaccine, one had received Moderna mRNA vaccine, and six had received inactivated vaccine. The symptoms developed after the first dose in 25 patients and after the second dose in 21 patients. Two patients developed adverse effects after both the first and the second dose. Systemic side effects of the vaccine were seen in 12 patients, the majority being mild cases of headache, myalgia, and fever. Valenzuela reported a case of acute macular neuroretinopathy in a patient who developed cervical and supraclavicular lymphadenopathy and difficulty in swallowing, which required treatment with prednisolone and diphenhydramine. [37] Uvea

The three cases of VKH following COVID-19 vaccination were characterized by the typical acute onset of bilateral painless loss of vision, anterior chamber granulomatous inflammation, and exudative retinal detachment [ Fig. 4 ]. Papasavvas reported a case of a 43-year-old female who had a past history of VKH, on infliximab and without inflammation for 6 years. There was a reactivation 42 days after the second dose of the mRNA vaccine. [20] Two of the three cases were following the mRNA Pfizer-BioNTech vaccine. All the cases were treated with systemic corticosteroids and resolved.

VKH is a T-cell-mediated multisystem autoimmune disease against melanocytes with ocular, neurological, audiovestibular, and dermatological manifestations. Viral infections have been known to trigger VKH with cytomegalovirus (CMV), influenza A, hepatitis C being implicated. [18] Antigenic cross-reactivity, HLA-DR4 status of patient (with influenza A), and interferon have been the mechanisms suggested in relation to viral infections causing VKH. Bacillus Calmette-Guerin (BCG) vaccine, influenza, hepatitis B, and yellow fever vaccinations have all been reported to cause cases of VKH, the onset ranging from 3 days to 4 weeks. [18] VKH after COVID-19 vaccination may be a result of T-and B-cell-induced hypersensitivity reaction, an inflammatory reaction to adjuvants in a vaccine, or sensitization to melanocytic antigens by viral antigens. mRNA-based vaccines do not have any viral antigens or adjuvants but induce humoral immunity, T helper (CD4 + cells) and cytotoxic T cell response which could potentially trigger the inflammatory response. [19] Uveitis Renisi et al. reported one of the earliest cases of anterior uveitis following both the first and second doses of the mRNA vaccine. The first episode was within a few hours of the first dose of the vaccine, whereas the second episode was delayed by 14 days from the date of vaccination. Systemic work-up for autoimmune diseases and serology for infections were negative, and it responded to topical corticosteroids and cycloplegics. [23] The second case reported by ElSheikh et al., triggered bilateral anterior uveitis in a patient with juvenile idiopathic arthritis (JIA) without any prior history of uveitis. This was after the second dose of the inactivated Sinopharm vaccine. [21] Jain et al. reported another case of JIA-associated uveitis in a 27-year-old male with HLAB27, 2 days after the Covishield vaccine. [22] A multicentric, retrospective study in Israel by Rabinovitch et al. [ reported 19 cases of anterior uveitis following vaccination by the BNT162b2 mRNA vaccine. [24] All the cases were classified as possible or probable consistent with the other articles where a definitive causal relationship with the vaccine could not be established. Two cases of panuveitis have also been reported. [25, 26] One of the patients had Behcet's disease and required azathioprine in addition to topical and oral corticosteroids for control of inflammation. [25] Thus, all three types of vaccines have been associated with uveitis.

Vaccine-induced uveitis is more common in females and is often seen when two or more vaccines are administered simultaneously. It has been seen most frequently after hepatitis B (40.5%) and human papillomavirus (15.6%) vaccines. [28] More than 200 cases of uveitis after the mRNA or vector-borne vaccines have been reported as per the US Food and Drug Administration Vaccine Adverse Event Reporting System. [28] In the review of published literature, a definite predilection for females was not observed. Only three patients had any known pre-existing autoimmune disease. In addition to the concept of molecular mimicry between the vaccine peptide fragments and uveal self-peptides, delayed hypersensitivity and immune complex deposition as triggers for the inflammation have also been suggested. [21] The role of vaccine-induced type 1 interferon secretion driving autoimmune phenotypes in the background of autoimmunity is another concept that may explain the high frequency of anterior uveitis after mRNA vaccines. The uveitis, however, is mild and easily controlled with topical corticosteroids and cycloplegics.

Two cases of multiple evanescent white dot syndrome (MEWDS) were reported by Rabinovitch et al. 24 Both presented shortly after the second dose and improved without any treatment.

In multifocal choroiditis, the pathological process lies in the retinal pigment epithelium (RPE). Two cases of bilateral choroiditis presenting 4-5 days after vaccination have been published. The case from India was in a healthy male who developed symptoms after the second dose of the viralvector-based vaccine, Covishield. The patient had systemic symptoms of headache, ocular pain, and pain at the injection site for 2 days after both doses of the vaccine. [27] The second case from China was following the first dose of the inactivated vaccine. [28] Both patients responded to corticosteroids.

In January 2021, Fowler et al. reported the only case of central serous chorioretinopathy in a 33-year-old healthy male after 3 days of the first dose of the mRNA vaccine. [29] The OCT and fluorescein angiography (FA) showed the typical features of CSCR. [Fig. 5 ] The patient was initiated on spironolactone, and it resolved in 3 months. In the absence of any other risk factor for CSCR, (space)like the use of corticosteroids or type A personality, the authors attributed it to the vaccine. [29] A second case of forme fruste CSCR has been reported by Pichi et al.after the Sinopharm inactivated COVID-19 vaccine. [16] Rare cases of CSCR after influenza, yellow fever, anthrax, and small pox Saraceno et al. [18] Letter to editor [19] Letter to editor Papasavvas et al. [20] Case report ElSheikh et al. [21] Letter to editor Jain et al. [22] Letter to editor Renisi et al. [23] Case report Italy 1 23 M

BNT162b2 mRNA

(1), 2

Rabinovitch et al. [24] Retrospective study Ishay et al. [25] Case series Mudie et al. [26] Case report Goyal et al. [27] Letter to editor Pan et al. [28] Case report Fowler et al. [29] Case report Pichi et al. [16] Case series Abu Dhabi

Bialasiewicz et al. [30] Letter to editor Endo et al. [31] Case report Goyal et al. [32] Letter to editor Patel et al. [34] Case report Vinzamuri et al. [35] Case report Book et al. [36] Images Germany Pichi et al. [16] Case series Abu Dhabi 3 (7)* OU CSCR with chronic serous PED in OS

Michel et al. [40] Case report Mishra et al. [41] Case report Maleki et al. [42] Case report Saraceno et al. [18] [30, 31] [ Fig. 6 ] Systemic vascular events have been reported following the adenoviral vector-based vaccines, but these are rare with mRNA vaccines with isolated cases being reported of deep vein thrombosis and thrombocytopenia. [43, 44] In the eye, both were following the Pfizer-BNT mRNA vaccine. One patient, with atopic dermatitis developed acute onset of pain, redness, and reduction of vision within a few minutes of administration of the second dose of the vaccine. Fundus examination showed a hemorrhagic CRVO and was treated with monthly intravitreal aflibercept injections and low dose acetylsalicylic acid as an antithrombotic measure. The retinal findings improved, and the patient is still under active treatment. [30] The second case was of a healthy 52-year-old male who developed nonischemic CRVO after 15 days of the first dose of the vaccine. He was treated with intravitreal corticosteroid injection initially, and intravitreal bevacizumab was added later along with oral apixaban. [31] This issue of Indian Journal of Ophthalmology (IJO) has a case of hemiretinal vein occlusion (HRVO)reported in a young healthy male following the second dose of Sputnik V vaccine. [32] The patient's blood work-up, inflammatory markers, and coagulation profile were unremarkable as was the history for any systemic diseases increasing the risk of vascular occlusive events. The patient had strongly positive antibodies IgG to the vaccine and may represent an unusually enhanced immune and possible inflammatory response to the vaccine. [32] The development of retinal vascular occlusions in patients with no other systemic risk factors suggests a possible association of the vaccine to the event.

AMN typically affects young women with changes observed in the optical coherence tomography (OCT)and subtle reddish wedge-shaped lesion directed towards the fovea on fundus evaluation with an ischemic origin in the deep capillary plexus or choriocapillaris. PAMMshows hyperreflective band-like lesions in the outer plexiform layer (OPL)/inner nuclear layer (INL) junction on OCT. [35] Thirteen cases of AMN following COVID-19 vaccine have been published to date. There was a definite female predilection (8 of 9 patients), and all of them gave a history of using contraceptives -oral or vaginal ring with ethinyl estradiol. [33, 34, 36, 37, 39] Oral contraceptives (OCPs) are a known risk factor for AMN and the vaccine-related inflammation may aggravate a pre-existing thrombophilic state in patients on OCPs. [34] The only male patient with the reported complication had simultaneous PAMM and had ocular manifestations after both doses of the vaccine. This case was also unique in that the ocular symptoms developed almost 4 weeks after the second dose of the vaccine. [35] The remaining five presented with the mild blurring of vision, paracentral scotomas, photopsia, and floaters within 3 days of the vaccination. Drüke et al. [38] reported a case of AMN in a 23-year-old female with JIA-associated iritis treated with methotrexate, sulfasalazine, and topical corticosteroids. This was the only patient who was treated with oral corticosteroid for the AMN, all others were observed with spontaneous resolution of the OCT findings. Eight patients received the viralvector-based vaccine (Janssen, Covishield, AstraZeneca). In the retrospective case series from Abu Dhabi by Pichi et al.,there are reports of three more patients who developed AMNand PAMM [ after the first dose of the inactivated Sinopharm vaccine. [16] Viral febrile illness (influenza, dengue, CMV, SARS-CoV-2), vasoconstrictors, [37] AMN has also been reported following influenza vaccination. [45, 46] Five patients had bilateral disease and normal anterior segment findings. The fundus is often normal, and the lesion is best appreciated in infrared reflectance. It is possible that many cases of AMN and PAMM are not diagnosed due to the lack of obvious ocular findings. Awareness of the disease and its association with vaccination, and a high degree of suspicion are essential for the diagnosis.

Mishra et al.reported the only case of ARN following the viral vector-based vaccine, Covishield, with reactivation of varicella-zoster infection in an immunocompetent male with a history of chickenpox 25 years ago. It was preceded by fever and myalgia after the vaccination. [41] ARN has been reported after the influenza vaccine and SARS-CoV-2 infection. A case series of seven adults developing varicella zoster virus (VZV) reactivation after COVID-19 vaccination has been published and involves a T-cell-mediated immune mechanism. [47] ARN may resolve spontaneously in immunocompetent patients. In the case of ARN reported, the anti-SARS-CoV-2 spike protein antibodies following vaccination were inadequate, and he was treated with valacyclovir, topical corticosteroids, cycloplegic, intravitreal ganciclovir, and oral corticosteroids. Firstly, it could be immunosenescence, and reduced thymic production of T-cells, which after vaccination caused a relative paucity of T-cell-mediated immunity at the site of VZV infection and its intraocular spread via long ciliary nerves. Secondly, an exhaustion of T-cells following vaccination could lead to a reactivation of VZV, leading to acute retinal necrosis. The third possibility could be a cross-reaction between COVID-19 anti-spike antibodies with varicella zoster spike glycoprotein amino acids amounting to anergy of T-cell-mediated immunity and subsequent reactivation of VZV. [41] Acute zonal occult outer retinopathy (AZOOR) A single case of bilateral AZOOR was documented by Maleki et al.in a healthy woman 10 days after vaccination with the Moderna mRNA-1273 vaccine. [42] There was a nasal visual field defect in the left eye, and multifocal electroretinography (ERG) showed defective areas ininferotemporal macula in the right eye and temporal macula in the left eye. OCT showed characteristic disruption of the outer retinal layers. The patient was treated with an intravitreal dexamethasone implant in the left eye. Elevated erythrocyte sedimentation rate (ESR) indicated the inflammatory nature of the pathology. T helper cells and cross-reacting antibodies against the outer retinal layers and retinal pigment epithelial cells were most likely involved in the pathogenesis.

Several posterior segment ophthalmic features of the COVID-19 infection have been reported and are associated with the procoagulant/prothrombotic state created by the cytokines released in response to the virus. The immune dysregulation induced by the virus can also lead to many of the ocular diseases described. The association of the vaccine with the rare retinal and uveal manifestations may be coincidental given the large scale of vaccination drive. However, the adenoviral vector vaccines have been associated with potentially life-threatening cerebral venous sinus thrombosis. [48] The pathogenesis is similar to the autoimmune heparin-mediated thrombocytopenia involving the activation of the coagulation cascade by the platelet-activating autoantibodies against platelet factor 4. The adverse event, vaccine-induced immune thrombotic thrombocytopenia (VITT) has been noted most frequently in young women within the first 3 weeks. The reported rate is close to five cases per million vaccinated adults (April 2021) for the AstraZeneca vaccine that contains chimpanzee replication-incompetent adenovirus without modification to mitigate the shedding of the expressed S protein. The S protein in the circulation can induce a proinflammatory/procoagulant response. [49] The rate is 0.87 cases per million for the Johnson and Johnson vaccine (April 2021) with human replication-incompetent adenovirus. The complication has not been reported with the mRNA-based vaccines.

Vaccine-related uveitis is not uncommon, both mild, transient anterior uveitis and more severe posterior and panuveitis have been reported. Stimulation of cytokine production, modification of surface antigens, and induction of new antigens with molecular mimicry to host tissue antigens, polyclonal B-cell activation, epitope spreading, bystander activation, and reaction to adjuvants are all the suggested mechanisms. [27] It was difficult to identify any specific trend other than the female gender and OCPs being used by the majority of the cases who developed AMN and association of the Pfizer mRNA vaccine with mild anterior uveitis. There may be multiple mechanisms at play simultaneously. Patients with a history of autoimmune diseases or JIA should be educated about the symptoms of floaters, scotoma, decreased contrast sensitivity, photopsia, and blurring of vision after vaccination and advised to seek medical attention at the earliest.

The COVID-19 vaccines have been observed to produce several neuro-ophthalmic manifestations. While most are transient, self-resolving, and mild, there are some that leave a residual effect. At present, there are 22 cases with neuro-ophthalmic adverse effects [ Table 4 ]. [39, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] These aside, Shemer et al.have reported 21 cases of patients with acute facial palsy following COVID-19 vaccination in a retrospective case-control study. [60] These cases have not been included in the Table 4 as all the details of the individual cases were not available. The mean age of the patients was 58.3 ± 20.6 (median 61.5) years with 11 males and 11 females. Thirteen patients had received the Pfizer mRNA vaccine, 4 had received Covishield, 3 inactivated CoronaVac from Sinovac, 1 Moderna mRNA vaccine, and 1 Covaxin. The events were equally distributed between the first (9) and second (8) doses, 1 patient developed facial palsy after both the first and second doses, and the dose status was not specified in 4 cases. The median interval of development of symptoms from the vaccination was 4 (mean 7.8 ± 8.1 ) days.

In the only reported case of AAION, a 79-year-old presented with bilateral loss of vision and optic disc pallor on examination 2 days after the second dose of the Pfizer-mRNA vaccine. The diagnosis was confirmed with elevated ESR and CRP and temporal artery biopsy. The authors attributed it to be an immune-mediated inflammation involving cross-reacting antibodies produced against the SARS-CoV-2 spike protein and helper T cells cross-reacting with proteins and antigens of large arteries. The patient was treated with high-dose intravenous methylprednisolone for 3 days followed by oral corticosteroids. [42] Optic neuritis Acute optic neuritis is an idiopathic disease presenting with painless vision loss and is usually unilateral and inflammatory. Leber et al.reported a case of bilateral optic neuritis with symptoms developing within 12 hours of vaccination with the second dose of inactivated CoronaVac vaccine. [50] The patient's infectious and inflammatory workup was unremarkable barring the detection of reactive MOG-IgG and elevated thyroid-stimulating hormone, antithyroglobulin, and antithyroid peroxidase. [50] The optic neuritis in this patient may be the initial manifestation of a demyelinating disorder associated with MOG-IgG, and the patient needs to be followed up for evaluation. She also had subacute thyroiditis which responded to the corticosteroid therapy. The second case of optic neuritis was in a healthy 28-year-old female after the first dose of vector-based Covishield vaccine. [53] Immune-mediated optic neuritis has been documented with BCG, hepatitis B, and tetanus vaccines.

Two separate cases of acute, unspecified, transient episodes of visual loss have been reported in middle-aged, relatively healthy males. The case reported by Santovito et al.was following the second dose of the Pfizer mRNA vaccine. [51] The patient had a prior history of COVID-19 infection. He developed fever with chills after the vaccination. The case description was subjective as no formal evaluation was done, and the patient presented after the spontaneous resolution the same day. There was sudden onset darkening of the visual field and visual distortion associated with nausea, light confusion, and asthenia. The second case was interesting because it was the self-observed report by an ophthalmologist who described the sudden onset of bilateral blurring of vision within an hour of the second dose of the CoronaVac vaccine. Computerized automated perimetry showed left congruous hemianopia respecting the vertical midline. The eye examination, OCT, neurological evaluation, blood investigations including lipid and coagulation profile, magnetic resonance imaging (MRI)were unremarkable. Only the blood pressure of the patient was elevated from the baseline to 150/90 mmHg. There was a spontaneous resolution, though the patient was admitted for observation, intravenous fluids, and oral aspirin. The author gives a logical and acceptable explanation -acute arterial vasospasm in the postchiasmatic visual pathway, most likely the right occipital lobe with macular sparing, with reperfusion to produce complete recovery. [52] Cranial nerve palsies Abducens nerve palsy Reyes-Capo et al.reported one case of acute abducens nerve palsy in a 59-year-old female, 2 days after vaccination with Pfizer mRNA vaccine. She developed sudden onset diplopia and right esotropia. Although the ESR and CRP were mildly elevated, her MRI was normal. [54] Two cases have been reported from India after the vector-based Covishield vaccine. [53] Abducens nerve palsy has been described following immunization with diphtheria-pertussis-tetanus (DPT), measles-mumps-rubella (MMR), hepatitis B, and influenza vaccine and can occur any time between 2 days and 3 weeks with spontaneous, slow resolution. An immune-mediated vasculitis, thrombosis, or demyelination have been proposed as possible mechanisms for the vaccine-associated nerve palsy.

Oculomotor nerve palsy Pappaterra et al. reported a case of partial, pupil sparing oculomotor nerve palsy in an 81-year-old male with hypertension, diabetes, and hypercholesterolemia, 4 days after the first dose of Moderna mRNA-1273 vaccine. [55] An MRI and MR angiography were done to rule out ischemic or aneurysmal compression. The patient gave a history of COVID-19 infection in the past, and the authors suggest reactivation of the COVID-19-associated immune phenomena with molecular mimicry. In an older individual with known risk factors, a microvascular ischemic event causing pupil sparing 3 rd nerve palsy is highly plausible. But the quick recovery and temporal association led the authors to consider the role of the vaccine. [55] Facial nerve palsy: Bell's palsy and Ramsay-Hunt syndrome Cases of facial palsy have been included in this review because of the ocular implications due to lagophthalmos [ Fig. 7 ]. Shemer et al.reported the largest series (9 cases) of facial nerve palsy after vaccination with Pfizer mRNA vaccine in Israel. [56] Bell's palsy is an acute, idiopathic, unilateral facial palsy often related to a preceding viral infection. The clinical features were typical, and cases of Bell's palsy responded well to prompt initiation of systemic corticosteroids. The ocular surface must be protected with liberal use of lubricants and night-time taping. Yu et al.reported the first case of Bell's palsy, following an inactivated vaccine in a patient who had a history of Bell's palsy in the past. [58] COVID-19 vaccine trials have documented cases of facial palsy, four with Pfizer-BioNTech and three with the Moderna mRNA vaccine compared to a single case in the placebo arm of the trial. [61, 62] Ozonoff et al.reviewed the vaccines trials and concluded that the observed incidence of Bell's palsy following mRNA vaccines was 3.5-7 times higher than the expected incidence in the general population (15-30/100000/year). [63] The risk is also higher after the second dose. In a retrospective case-control study, Shemer et al. found no association between vaccination with BNT162b2 mRNA vaccine and development of new-onset facial palsy after adjustment for pre-existing immune or inflammatory diseases, diabetes, and previous episode of peripheral nerve palsy. [60] Like the other ophthalmic manifestations, Bell's palsy is not unique to the COVID-19 vaccine and has been described post influenza, hepatitis B, polio, DPT, and MMR vaccines. Conflicting and limited available data make definitive conclusions about a causal relation difficult. The autoimmune process with host cell mimicry, bystander activation of dormant autoreactive T-cells, or induction of innate immunity and interferon production by the combined effect of mRNA and lipids, could be responsible for the resultant facial nerve palsy.

Ramsay-Hunt syndrome is caused by reactivation of latent VZV in the geniculate ganglion and is characterized by a Sen Maleki et al. [42] Case report Leber et al. [50] Letter to editor Santovito et al. [51] Letter to editor Jumroendararasame et al. [52] Case report Pawar et al. [53] Letter to editor Reyes-Capo et al. [54] Case report Shemer et al. [56] Case report Ish et al. [57] Letter to editor Yu et al. [58] Case report Rodríguez-Martín et al. [59] Letter to editor [59] In addition to the cases elaborated in the table, Thunstedt el al reported a case of raised intracranial pressure in a healthy 23year old male a week after receiving the AstraZeneca ChAdOx 1 vaccine. Despite bilateral papilloedema, the patient had normal vision. Headache is a common side effect after the COVID-19 vaccines. However, persistent and pulasatile headache demands complete evaluation to rule out cerebral venous thrombosis, meningitis and drug related raised intracranial tension with CSF analysis and neuroimaging. Patient was successfully treated with acetazolamide and torsemide. [64] Orbital Manifestations of COVID- 19 Vaccine Orbital complications are uncommon, and there are four published reports to date. [ Table 5 ] [65] [66] [67] [68] The mean age affected was 44.6 ± 11.3 (median 47.5) years with 3 females.

There was one case each following the two mRNA vaccines from Pfizer and Moderna. Both cases of superior ophthalmic vein thrombosis (SOVT) were following vaccination with ChAdOx1 nCoV-19 vaccine. [67, 68] Information about the vaccine dose was available for three patients, two of them were following the first dose and one after the second dose.

The onset of symptoms was at a median of 6 (mean 6.3 ± 3 ) days from the time of vaccination.

Rubinstein et al. [ reported a case of thyroid eye disease in a patient with a history of Graves' disease for 11 years but without any ophthalmic involvement. [65] The onset of eyelid edema, proptosis, ptosis, and diplopia were within 3 days of the second dose of vaccine. Thyroid ophthalmopathy was confirmed on clinical examination (CAS 5), computed tomography (CT) scan, and elevated serum thyroid-stimulating immunoglobulin. The patient responded to teprotumumab.

Chuang et al.reported a case of Tolosa-Hunt syndrome following vaccination. [66] [ Fig. 8 ] A granulomatous inflammatory process involving the cavernous sinus remains a diagnosis of exclusion and responds to corticosteroids. Spontaneous remission has been reported.

Patients with SOVT present with headache, proptosis, ophthalmoplegia, diplopia, and diminished vision and filling defect on CEMRI with a dilated SOV confirms the diagnosis. Two cases of superior ophthalmic vein thrombosis after the viral vector-based vaccine ChAdOx1 nCov-19 vaccine have been published. In the report by Panovska-Stavridis et al., the patient had thrombocytopenia, high D-dimer levels, and platelet factor 4 antibodies. [68] She was treated with intravenous immunoglobulin (IVIG) and tapering doses of oral corticosteroids. The second patient was an older female, fifty-five-year-old with features suggestive of secondary immune thrombocytopenia. She was treated with heparin but developed ischemic stroke. [67] As discussed in the previous section, cases of CSVT after the adenoviral vector vaccines have been described and are amongst the most serious adverse effects. Thrombotic Chuang et al. [66] Case report Bayas et al. [67] Clinical picture Panovska-Stavridis [68] Letter to editor Republic of North Rubinstein [65] OU Irritation, tearing, orbital pain, abduction limitation, proptosis, normal thyroid functions, normal inflammatory markers. CT-OS>OD enlarged IR, MR without tendon involvement or sinus disease.

Thyroid eye disease IV teprotumumab Improvement in congestion and proptosis Chuang et al. [66] OS Severe left sided headache, progressive ptosis, decreased vision, RAPD, complete ophthalmoplegia. Inflammation and infection markers normal. Elevated CRP. CT and MRI Tolosa Hunt syndrome Initially antibiotics-discontinued after results of blood and CSF. IV methylprednisolone 1 g x 3 days-oral Pain decreased. Improvement in cranial nerve deficit over 2 monthspartial recover, on follow up

Bayas et al. [67] OU Conjunctival congestion, retro-orbital pain and diplopia. thrombocytopenia is an immune-mediated post-vaccination complication. A multicentric cohort study by Perry et al found that patients with VITT related CSVT were more likely to have received the ChAdOx1 vaccine, younger, without systemic risk factors, had more extensive venous thrombosis, intracranial hemorrhage and more concurrent extracranial and arterial thrombosis with worse outcome as compared to patients without VITT associated CSVT. The outcome improved with use of IVIG and non-heparin anticoagulants. [69] Ophthalmologists should be aware of the occurrence of such thrombotic events. Frequently, they may be the ones to diagnose the condition which may pre-empt fatal cerebral ischemia.

Patients with underlying thyroid disease should undergo a baseline ophthalmic examination before vaccination and be informed about the possibility of thyroid eye disease flaring.

Ocular manifestations of the COVID-19 vaccine are not uncommon but relatively mild and transient except for cases of retinal and ophthalmic vascular occlusions and graft rejections. In a cross-sectional study based on an online survey questionnaire, Kadali et al. found that of the 803 healthcare workers who received the BNT162b2 mRNA vaccine, very few had non-specific ocular symptoms of blurred vision (4/803, 0.5%), eye pain (7/803, 0.87%), and flashes (2/803, 0.25%). [70] A similar study on 432 healthcare workers who received the mRNA-1273 vaccine showed that frequency of ophthalmic side effects was rare (eye pain: 15/432, 3.47%), to extremely rare (blurring of vision: 4/432, 0.93%; flashing lights: 3/432, 0.69%). [71] The posterior segment, the retinal vasculature, and the uvea are most frequently affected. Comparison by age shows that patients with posterior segment manifestation were relatively younger (mean age 43.6 years) as compared to patients with neuro-ophthalmic lesions (mean age 58.3 years) and corneal graft rejections (mean 65 years). The median time for the development of ocular signs and symptoms was 7 days for eyelid, ocular surface, and anterior segment, 6 days for orbit and 4 days for the posterior segment and neuroophthalmological cases. These details are important to follow up high-risk patients in the ophthalmic clinic. [ Fig. 9 ] Patients with corneal grafts should be followed within a week, whereas those with JIA or prior history of uveitis need to be called in earlier.

The vaccines have been found to be safe before receiving approval from the appropriate authority. Adverse effects following vaccination are infrequent, benign, transient, and treatable. Serious adverse effects including anaphylaxis and thrombocytopenia are rare. The ocular manifestations have been attributed to molecular mimicry (similarities in the structure of SARS-CoV-2, human or chimpanzee adenoviral components), antigen-specific cell, and antibody-mediated hypersensitivity reactions to spike antigen, or other viral antigens and adjuvants present in the vaccines that enhance immunogenic activity. The mechanisms are similar to those seen with various other vaccines that have been used for several years including influenza, MMR, hepatitis A and B, yellow-fever, BCG, DPT, and HPV. Almost all the manifestations have been managed conservatively or with steroidal and nonsteroidal immunosuppressants.

That being said, it is important to report all manifestations to improve the knowledge base of physicians and patients. For ophthalmologists, this awareness is necessary to be able to counsel patients for vaccination, informing them of the possible symptoms for early presentation, diagnosis, and initiation of treatment. Patients with corneal grafts can be started on frequent topical corticosteroids a week before vaccination, and this can be tapered slowly after the second dose. Those who require non-urgent corneal transplantation may be scheduled after 4-6 months of the completion of all doses of vaccination. Patients with a history of inflammatory eye diseases should be warned of possible reactivation or recurrence and educated about early symptoms. Knowledge about the adverse effects is also important to encourage patients for vaccination and counter false information.

It is encouraging to note that all the authors have reported with great maturity, highlighting rightly that the causal relationship of all the manifestations to the COVID-19 vaccine are only possibilities and not established with certainty because of the lack of large-scale real-world studies. They have also vehemently supported the need for every individual to get vaccinated as the benefits far outweigh the risks. Responsible reporting is the need of the hour.

As further information is acquired and shared, the long-term implications of the vaccines will become more clear. Patients who developed the signs after the first dose need to be followed up after the second dose to document if they had a similar reaction or not. This will throw further light on the true association of the vaccines with the ocular events as well as the risk factors for the same. It may also be prudent to classify the associations as possible, probable, definite, or unrelated as more cases come to light. Corneal graft rejection after the first dose raises the question of the timing of the second dose. The permanent or residual effects of the manifestations are also to be determined.

From the review of cases, it is evident that a maladaptive immune system at work in response to the vaccine may reactivate some autoimmune diseases in the patients like uveitis, thyroid ophthalmopathy, and thrombocytopenic thrombosis. New-onset uveitis may be the first sign of an underlying autoimmune disease. This raises the question of the need for complete systemic evaluation of a patient with uveitis following vaccination. COVID-19 vaccines do not have any live virus and therefore, individuals on immunomodulators can have the vaccine safely, but the efficacy in them may be questionable. [4] The currently available studies have not demonstrated an increased risk of reactivation following vaccination with COVID-19 including in patients with multiple sclerosis. [72] New vaccines are on the horizon, booster doses are definite in the near future, and children are soon to be vaccinated, creating a platform for a plethora of new and exciting information. As of October 29, 2021, there are 128 vaccines in clinical development and 194 vaccines in the preclinical development stage. [3] Many of the adverse events are treated with immunosuppressants, and one is curious to see if the vaccine efficacy is affected by drugs used for the reactions like corticosteroids, and teprotumumab. With travel also returning to the forefront, the mixing of vaccines may also bring about more information.

COVID-19 vaccines are a boon that needs to be studied, improved, and harnessed to their full potential for safety as well as returning to as normal a life as possible. As ophthalmologists, we need to be aware of the emerging manifestations and complications pertaining to the eye following the vaccination with different vaccines, to be better prepared to diagnose, manage, and give correct information to patients.

Nil.

There are no conflicts of interest.

COVID-19 and eye: A review of ophthalmic manifestations of COVID-19

Transient eyelid edema following COVID-19 vaccination

Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: Another piece of SARS-CoV-2 skin puzzle

Corneal graft rejection following COVID-19 vaccine

Bilateral EK rejection after COVID-19 vaccine

Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine

Keratoplasty rejection after the BNT162b2 messenger RNA vaccine

Corneal graft rejection after COVID-19 vaccination

Acute corneal endothelial graft rejection following COVID-19 vaccination

Acute graft rejection in a high-risk corneal transplant following COVID -19 vaccination: A case report

Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi

Vogt-Koyanagi-Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine

Vogt-Koyanagi-Harada disease associated with COVID-19 mRNA vaccine

Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination

Acute uveitis following COVID-19 vaccination

COVID-19 vaccine-associated reactivation of uveitis

Anterior uveitis onset after bnt162b2 vaccination: Is this just a coincidence?

Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: A possible association

Autoimmune phenomena following SARS-CoV-2 vaccination

Panuveitis following vaccination for COVID-19

Bilateral multifocal choroiditis following COVID-19 vaccination

Bilateral uveitis after inoculation with COVID-19 vaccine: A case report

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine

Central retinal vein occlusion occurring immediately after 2 nd dose of mRNA SARS-CoV-2 vaccine

Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report

Unilateral retinal vein occlusion in a young, healthy male following Sputnik V vaccination

Acute macular neuroretinopathy following coronavirus disease 2019 vaccination

Acute macular neuroretinopathy following SARS-CoV-2 vaccination. Retin Cases Brief Rep

Bilateral paracentral acute middle maculopathy and acute macular neuroretinopathy following COVID-19 vaccination

Bilateral acute macular neuroretinopathy after vaccination against SARS-CoV-2

Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination

Acute macular neuroretinopathy (AMN) following COVID-19 vaccination

Acute macular neuroretinopathy following COVID-19 vaccination

Acute macular neuroretinopathy after COVID-19 Vaccine

Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male

COVID-19 recombinant mRNA vaccines and serious ocular inflammatory side effects: Real or coincidence?

Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Acute macular neuroretinopathy following the administration of an influenza vaccination

Acute macular neuroretinopathy associated with influenza vaccination with decreased flow at the deep capillary plexus on oct angiography

Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel) 2021

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: Causation or coincidence?

Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with CoronaVac: A case report

Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2 nd dose: A case report

Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report

Ophthalmic complications of COVID-19 vaccination

Acute abducens nerve palsy following COVID-19 vaccination

Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273

Vaccine for SARS-CoV-2 Diplopia Following the COVID-19

Epub ahead of print

Peripheral facial nerve palsy following BNT162b2 (COVID-19) vaccination

Facial nerve palsy after COVID19 vaccination -A rare association or a coincidence

Bell's palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell's palsy: A case report

Ramsay Hunt syndrome following mRNA SARS-COV-2 vaccine

Association of COVID-19 vaccination and facial nerve palsy: A case-control study

Vaccines and Related Biological Products Advisory Committee Meeting-FDA Briefing Document

62. Vaccines and Related Biological Products Advisory Committee Meeting

Bell's palsy and SARS-CoV-2 vaccines

Isolated intracranial hypertension following COVID-19 vaccination: A case report

Thyroid eye disease following COVID-19 vaccine in a patient with a history Graves' disease: A case report

Tolosa-Hunt syndrome presenting after COVID-19 vaccination

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. The Lancet

Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers

Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross sectional study on healthcare workers with detailed self-reported symptoms

Ocular adverse events after COVID-19 vaccination

Several COVID-19 vaccines have been developed and approved for use around the world from December